NWBO · XBRL financial data
Northwest Biotherapeutics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NWBO's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 2 | 2 | — | — |
| Revenue from contracts with customers | — | — | — | 2 | 1 | 1 |
| Research and development | 34 | 20 | 36 | 28 | 35 | 29 |
| General and administrative | 51 | 33 | 33 | 30 | 33 | 33 |
| Operating income (loss) | (87) | (53) | (67) | (56) | (67) | (60) |
| Interest expense | 9 | 5 | 6 | 5 | 8 | 9 |
| Other income (expense) | (443) | 232 | (38) | (7) | (17) | (1) |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | (1) |
| Net income (loss) | (530) | 179 | (105) | (63) | (84) | (60) |
| Earnings per share, basic USD per share | (0.73) | 0.21 | (0.10) | (0.06) | (0.07) | (0.04) |
| Earnings per share, diluted USD per share | (0.73) | (0.06) | (0.10) | (0.06) | (0.07) | (0.04) |
| Weighted average shares, basic millions of shares | 1 | 1 | 1 | 1 | 1 | 1,457 |
| Weighted average shares, diluted millions of shares | 1 | 1 | 1 | 1 | 1 | 1,457 |
Balance sheet
CSVFiscal years (NWBO's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 10 | 15 | 7 | 2 | 2 | 3 |
| Prepaid and other current assets | 6 | 2 | 2 | 2 | 2 | 2 |
| Total current assets | 16 | 17 | 9 | 4 | 4 | 6 |
| Property and equipment, net | 1 | 15 | 13 | 17 | 16 | 17 |
| Right-of-use asset | 4 | 5 | 4 | 4 | 4 | 4 |
| Goodwill | 1 | 1 | 1 | 1 | 1 | 1 |
| Total assets | 33 | 40 | 31 | 28 | 27 | 81 |
| Total current liabilities | 382 | 134 | 126 | 45 | 68 | 92 |
| Lease liability, non-current | 5 | 5 | 4 | 4 | 4 | 4 |
| Total liabilities | 396 | 164 | 136 | 75 | 106 | 129 |
| Accumulated deficit | (1,371) | (1,192) | (1,297) | (1,360) | (1,443) | (1,504) |
| Total stockholders' equity | (363) | (124) | (128) | (66) | (94) | (60) |
| Total liabilities and equity | 33 | 40 | 31 | 28 | 27 | 81 |
| Common shares outstanding (cover page) millions of shares | 842 | 960 | 1,073 | 1,190 | 1,391 | 1,607 |
Cash flows
CSVFiscal years (NWBO's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (530) | 179 | (105) | (63) | (84) | (60) |
| Stock-based compensation | — | — | 3 | 4 | — | — |
| Net cash from operating activities | (32) | (38) | (53) | (54) | (57) | (45) |
| Purchases of property and equipment | — | — | — | — | 1 | 2 |
| Net cash from investing activities | (8) | (6) | (3) | (3) | (1) | (2) |
| Proceeds from issuing common stock | — | — | — | — | 14 | 19 |
| Net cash from financing activities | 53 | 48 | 42 | 53 | 57 | 49 |
| Net change in cash | 10 | 5 | (8) | (5) | 0 | 1 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Northwest Biotherapeutics | 0.6 | 0.8 | (7.2)* | 1.7B | 0.1 quarters | 10-QJun 30, 2026 |
| Emergent BioSolutions | 176 | 110 | 100* | 51.4M | — | 10-QSep 30, 2026 |
| Amarin | 157 | 40 | 9.2* | not reported | — | 10-QSep 30, 2026 |
| Rigel Pharmaceuticals | 61 | 79 | 31* | 18.7M | — | 10-QJun 30, 2026 |
| Usana Health Sciences | 169 | 223 | 23* | 18.5M | — | 10-QJul 4, 2026 |
| Altimmune | 63 | not reported | (24)* | 194.5M | 13.5 quarters | 10-QJun 30, 2026 |
| Prothena Corp Public | 288 | 1 | (25)* | 51.3M | 11.5 quarters | 10-QJun 30, 2026 |
| Aura Biosciences | 68 | not reported | (33)* | 103.7M | 2.1 quarters | 10-QJun 30, 2026 |
| Nektar Therapeutics | 39 | 10 | (76)* | 34.1M | 9.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.